Corvus Pharmaceuticals, Inc. (CRVS) Stock Score, Valuation & Financial Research

Corvus Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for CRVS

Corvus Pharmaceuticals, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 10.56. These figures are a research snapshot, not a buy or sell recommendation.

What Corvus Pharmaceuticals, Inc. does

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on research and development of small-molecule and monoclonal antibody product candidates, funded through capital raises, and it expects to eventually generate revenue through the commercialization of these therapies if approved by regulatory authorities.

Products and services

  • The company is developing a pipeline of oncology and immunology product candidates, including soquelitinib (an ITK inhibitor), ciforadenant (an A2A receptor antagonist), and mupadolimab (an anti-CD73 antibody).

Customer types

Cancer patients; Healthcare providers.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturers for the production of clinical trial materials and future commercial supply; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Angel Pharmaceuticals — A strategic collaboration in China where Angel Pharmaceuticals develops and commercializes certain Corvus product candidates in that territory. Source

Competitors and product-market comparisons

  • Biopharmaceutical companies — The company competes with various biopharmaceutical and pharmaceutical companies developing oncology and immunology therapies. Source

Business strengths to evaluate

  • Proprietary pipeline of clinical-stage product candidates Source
  • Strategic collaboration with Angel Pharmaceuticals for the Chinese market Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on third-party contract manufacturers Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

CRVS financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 10.56
Market capitalization:
887.99M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -54.13M
Free cash flow:
USD -32.97M
Cash:
USD 18.91M
Total debt:
USD 728K
EPS:
USD -0.64

What stands out

  • Free cash flow is USD -32.97M, negative for the stored period.
  • The balance sheet shows USD 18.91M of cash versus USD 728K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 18.18M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for CRVS

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can CRVS fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is CRVS likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for CRVS to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of CRVS's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research CRVS

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.